Back to Results
First PageMeta Content
Gastroenterology / Colitis / Abdominal pain / Ulcerative colitis / Inflammatory bowel disease / Immunosuppressants / Mesalazine / Ulceration / Infliximab / Health / Medicine / Autoimmune diseases


May 13, 2014 Ajinomoto Pharmaceuticals Co., Ltd.
Add to Reading List

Document Date: 2014-05-13 01:55:34

Open Document

File Size: 221,36 KB

Share Result on Facebook

City

Tokyo / Chicago / /

Company

Ajinomoto Pharmaceuticals Co. Ltd. / Ajinomoto Pharmaceuticals Co. / /

Country

Japan / United States / /

/

Event

FDA Phase / /

Facility

Dental University / /

IndustryTerm

treatment of inflammatory bowel disease / /

MedicalCondition

ulcerative colitis / inflammatory bowel disease / moderately active ulcerative colitis / Active Ulcerative Colitis / disease / severe infections / active ulcerative colitis Study design A / /

Organization

Tokyo Medical and Dental University / /

Person

Mamoru Watanabe / Takashi Nagamachi / /

/

Position

Professor of Gastroenterology and Hepatology / President / /

Product

AJM300 / /

SocialTag